Iwanderer, For right now none of us know what Denner and AMRN's BOD are
doing. For all we know they may have reached some type of compromise. If
not, then Denner may decide to become more aggressive. At least now Denner
is in the same boat as most AMRN shareholders with massive losses on their
investment in AMRN. Basically, AMRN is a case of bad management destroying
what should have been a great-drug opportunity. Will AMRN bad management do
the same with Europe? I for one would rather have a Euro-centric BP own AMRN
at this point rather than find out that management destroyed Europe as well.
So far I am disappointed by KM as CEO. I have much less confidence in KM
from his decision not to engage with Alex Denner. (That is not good and speaks
poorly for KM.) As has always been my Thesis AMRN must be owned by a BP
in order that the uptake of Vacepa is optimized. (My "hope" is that Denner
beleves the same and does something about it.)